Pharmaceutical Technology Europe-02-01-2006

Pharmaceutical Technology Europe

The regulating authorities have, it seems, a preference for the application of multimembrane combinations to maximize organism retentions.

Pharmaceutical Technology Europe
Talking Point

February 01, 2006

If delaying the project has little consequence then you should probably not run the project in the first place.

Pharmaceutical Technology Europe

Latin America has become a promising region for the pharmaceutical industry in terms of both R&D and sales. Nowhere has this been more apparent than in Mexico, which has become a top priority market for many of the major multinational pharmaceutical companies. Furthermore, the Mexican government is increasing its investment in healthcare resources and there is a strong, growing demand from the population for access to newer and better medical treatments.

Pharmaceutical Technology Europe

Although physicochemical preformulation screening is practised universally within the pharmaceutical industry, physicomechanical screening is applied to a lesser extent and often only where a problem exists.

Pharmaceutical Technology Europe
Regulatory Report

February 01, 2006

Baselines are one of the most useful tools in the 'validation toolbox'. They can be used for a variety of tasks with great success. This article will examine how they can be used and for what.

Pharmaceutical Technology Europe
Editorial

February 01, 2006

It's all well and good providing drugs for people who need them, but it becomes a lot more difficult if they choose to ignore the warnings

Pharmaceutical Technology Europe
Opening News

February 01, 2006

Chewing gum is being developed by Generex as an alternative buccal drug delivery method of metformin for treating diabetes. Results from a small clinical trial, which compared pharmacokinetic profiles of metformin gum with its traditional tablet form, suggest that the gum could additionally avoid the significant adverse gastrointestinal side-effects, including diarrhoea and nausea/vomiting, often accompanying the use of metformin tablets. Given that approximately 30% of metformin users experience such unwanted effects, the gum version could improve patient compliance.

Pharmaceutical Technology Europe
Industry News

February 01, 2006

The European Science Foundation (ESF) has published the conclusions of its 2-year Forward Look Study on Nanomedicine. Defined as a billionth of a metre, a nanometer is 1000 times smaller than the width of a human hair. Nanomedicine uses nanoscale technology to diagnose and treat disease. The scope of the study included defining the field of nanomedicine, reviewing what has been achieved so far, determining Europe's strengths and weaknesses, and drawing up plans to ensure continued growth.

Pharmaceutical Technology Europe
Regulatory News

February 01, 2006

Small- and medium-sized enterprises (SMEs) will gain administrative and procedural assistance from the EMEA. The agency's SME office was launched in December 2005 and follows the new Commission Regulation, which aims to promote the development of medicinal products in SMEs.

Pharmaceutical Technology Europe
Tissue Culture

February 01, 2006

There are over 250 operations in the EU in various stages of development involving tissue engineering, regeneration and subsequent attempts at commercialization.

Pharmaceutical Technology Europe

The type of robot used for placing and stacking the BFS cards is important. Conventional multi-axes designs have limited flexibility, often combined with high inertia that limits operating speeds.

Pharmaceutical Technology Europe
Formulation

February 01, 2006

Aggregation or coagulation of drug particles in a parenteral suspension can pose a serious threat to product quality, particularly for products that require extended shelf life. In the worst case, aggregation can lead to the formation of a nonresuspendable sediment, known as caking. Controlling physical stability is difficult because of the complexity of this phenomenon. This article gives an overview of the factors that were found to be the most important in our search to improve the physical stability of a pharmaceutical suspension.

Pharmaceutical Technology Europe
Bio News

February 01, 2006

The total area of land planted with biotech crops was up 11% in 2005. An extra 17 billion m2 of crops were planted, contributed to by 250000 new farmers and four new countries. The most popular genetically modified crop remained herbicide tolerant soybeans, which made up 60% of the total global area. Maybe the most significant new planting of 2005 was the Iranian crop of biotech rice — the staple foodstuff of the world's poorest people. The crop could possibly help in the UN's Millennium development goal to reduce poverty, hunger and malnutrition by 50% by 2015.